Phase II Study of Intrathecal I-3F8 [monoclonal-antibody-3F8-I-131] in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Monoclonal antibody 3F8 I-131 (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- 22 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 22 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.